Atlas Trials

A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects

Clinical trial NCT00955773 · COMPLETED

Trial details

NCT number
NCT00955773
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Cancer
Start date
2009-08-17
Primary completion
2011-11-08
Enrollment
64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.